Details of the Drug Combination

General Information of Drug Combination (ID: DCP4GGF)

Drug Combination Name
Nitazoxanide Favipiravir
Indication
Disease Entry Status REF
Covid19 Phase 2 [1]
Component Drugs Nitazoxanide   DMOWLVG Favipiravir   DMBZ27L
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Nitazoxanide
Disease Entry ICD 11 Status REF
Clostridioides difficile infection 1A04 Approved [2]
Cryptosporidium infection 1A32 Approved [2]
Diarrhea DA90 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [4]
Giardiasis N.A. Investigative [2]
Nitazoxanide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) TT0F5P8 PNO_CRYPV Modulator [6]
------------------------------------------------------------------------------------
Nitazoxanide Interacts with 7 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [7]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [8]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [7]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Affects Response To Substance [9]
Dedicator of cytokinesis protein 8 (DOCK8) OTNQLL21 DOCK8_HUMAN Affects Response To Substance [9]
Slit homolog 3 protein (SLIT3) OTU8MKEU SLIT3_HUMAN Affects Response To Substance [9]
Sushi domain-containing protein 6 (SUSD6) OTZS4SKF SUSD6_HUMAN Affects Response To Substance [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DOT(s)
Indication(s) of Favipiravir
Disease Entry ICD 11 Status REF
Influenza virus infection 1E30-1E32 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Favipiravir Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Modulator [10]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04918927) Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19
2 Nitazoxanide FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 ClinicalTrials.gov (NCT04382846) Novel Regimens in COVID-19 Treatment. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009 Nov;137(5):1827-35. doi: 10.1053/j.gastro.2009.07.056. Epub 2009 Aug 4.
8 Identification of Modulators That Activate the Constitutive Androstane Receptor From the Tox21 10K Compound Library. Toxicol Sci. 2019 Jan 1;167(1):282-292. doi: 10.1093/toxsci/kfy242.
9 Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
10 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
11 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.